Asia Pacific Organoids Services Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis.
No. of Pages: 136 | Report Code: BMIRE00032025 | Category: Life Sciences
No. of Pages: 136 | Report Code: BMIRE00032025 | Category: Life Sciences
The Asia Pacific organoids services market size is expected to reach US$ 2,327.10 million by 2031 from US$ 515.83 million in 2024. The market is estimated to record a CAGR of 24.0% from 2024 to 2031.
The Asia Pacific organoids services market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. The market in the region is likely to grow at the fastest rate during the forecast period owing to factors such as the increasing use organoids, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoids products, and an upsurge in the funding for organoids research.
Key segments that contributed to the derivation of the Asia Pacific organoids services market analysis are type, application, and source.
The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed below:
In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products as needed.
In May 2024, InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research.
In January 2024, HUB Organoids (HUB) launched IntegriGut Screen services for the global market. This screening service employs IBD patient-derived organoid monolayers—PDO Monolayers—to aid in the availability of high-quality human data on epithelial barrier function, in turn accelerating the development of novel IBD therapies.
In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.
In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition.
In December 2022, Molecular Devices, LLC. acquired Cellesce Ltd. This acquisition focuses on producing large-scale PDOs for various purposes, including drug screening, through contract development and production services.
In August 2021, STEMCELL Technologies and Hubrecht Organoid Technology (HUB) signed an agreement. As a part of this agreement, STEMCELL's Contract Assay Services division began providing its tissue-derived organoids, such as lung, intestinal, and liver organoids, for pre-clinical toxicology screening and non-cancer drug development services to HUB. These services would facilitate the integration of organoids into preclinical testing programs by researchers and drug development organizations to aid in the faster and more economical launch of new therapies.
In May 2020, CELLINK collaborated with AstraZeneca to provide advanced 3D bioprinted liver organoids for drug discovery purposes in metabolic diseases, renal, and cardiovascular diseases. This collaboration allowed AstraZeneca to use Extra Cellular Matrix and Laminin-based bioinks from CELLINK. These are novel and patent-pending bioinks that allow human cells to proliferate and behave similarly to their behavior in the human body.
In February 2020, InnoSer and OrganoTherapeutics announced a collaboration to provide midbrain organoids for drug discovery and screening. This collaboration was meant to make midbrain organoids commercially available as a platform for Parkinson's disease research.
Such key developments, launches, and strategic collaborations among market players create ample opportunities for the organoid services market growth.
Based on Country, the Asia Pacific Organoids Services Market comprises Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held the largest share in 2024.
In Asia Pacific, China dominates the organoids services market, and the market growth in this country is primarily attributed to the increasing popularity of personalized medicine that spur research and development in organoids. In September 2020, HUB and BGI-Qingdao inked a Memorandum of Understanding (MoU) to establish a joint next-generation diagnostics (NGD) center to provide improved personalized care with better treatments and cures and aid in faster development of novel, safe medicines in China. With their complementary expertise and technology, HUB and BGI plan to further develop and implement HUB Organoid Technology as predictive diagnostic tests, initially allowing for accurate patient-specific prediction of treatment responses with a focus on cancer. Similarly, in October 2020, IBP Laboratory was introduced to model brain organoids and cultivation technologies. Research studies on gene mutation and cancer research will also favor the market expansion in China. China launched a robot named "Organoid" in July 2024, which was given a human brain in a lab. This invention represents a significant advancement toward creating hybrid machines capable of doing various activities independently. According to reports from The Sun, researchers at Tianjin University and Southern University of Science and Technology developed this robot. The robot's brain organoid was created using human stem cells and a neural interface device. The purpose of this combination is to enable the robot to do complex tasks such as item grasping and obstacle avoidance. Such developments are expected to propel the demand for organoid services in China in the coming years.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 515.83 Million |
| Market Size by 2031 | US$ 2,327.10 Million |
| Global CAGR (2024 - 2031) | 24.0% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Asia Pacific
|
| Market leaders and key company profiles |
Some of the key players operating in the market include CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The Asia Pacific Organoids Services Market is valued at US$ 515.83 Million in 2024, it is projected to reach US$ 2,327.10 Million by 2031.
As per our report Asia Pacific Organoids Services Market, the market size is valued at US$ 515.83 Million in 2024, projecting it to reach US$ 2,327.10 Million by 2031. This translates to a CAGR of approximately 24.0% during the forecast period.
The Asia Pacific Organoids Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Organoids Services Market report:
The Asia Pacific Organoids Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Organoids Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Organoids Services Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Organoids Services Market
